Dublin-anchored Lynskey Engineering to be snapped up by German giant
The deal, which is subject to regulatory approval and was notified to the competition watchdog on Wednesday, is expected to be completed in the third quarter, the Berlin-headquartered company said in a statement on Thursday morning.
The purchase price is confidential, the firm said. Lynskey generated an annual turnover of more than €57 million, according to its most recently available set of accounts, and currently employs around 120 people across the group.
Based on the Kylemore Road in Dublin 10, Lynskey specialises in mechanical building services and electrical engineering. It has delivered projects for multinationals including Kerrygold-maker Ornua at its facility in Mitchelstown, Cork, as well as Penneys owner Primark, and LinkedIn, according to its website.
READ MORE
Dussmann, which reported annual revenues in excess of €3 billion in 2024, first entered the Irish market in 2019 with the acquisition of STS Group, a Waterford-based firm.
Sean McElligott, Lynskey's managing director and controlling shareholder, said the deal presents the Irish firm with an 'excellent opportunity' growth.
He said: 'Our clients will continue to enjoy the same level of superior service provided by our team, delivering complex technical mechanical projects within time and on budget, and will, post-acquisition, also benefit from the increased scale and service capability we can offer as part of a circa €3.3 billion turnover group.
'Similarly, our employees will find increased opportunities provided by the ambition and support of Dussmann to grow our business further.'
The deal will see Lynskey join Dussmann's technical solutions division, which incorporates a number of different services across the life cycle of factories and other facilities like data centres, from design to installation and technical maintenance.
Stephan Possekel, managing director at Dussmann Technical Solutions, commented on the planned acquisition, said the German firm has already worked closely with Lynskey on several projects in the data centre sector.
'Lynskey's portfolio of mechanical services seamlessly complements STS's electrical engineering services', he said.
Oliver Finckh, chief technical officer and managing director, said: 'The acquisition of Lynskey will enable us to offer both main trades – mechanical as well as electrical services on complex large-scale projects, thus being a single source provider of mechanical, electrical, and plumbing services.'
Lynskey was advised by Anglesea Corporate Finance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
2 hours ago
- Irish Times
Gareth Sheridan: Nutriband ‘will help a lot of people who are dealing with addiction and people who are dealing with pain'
Nutriband is a pharmaceutical company that was founded in Dublin in 2012 before relocating to Florida in 2016. Gareth Sheridan, who recently announced his intention to run for president and has stepped aside for three months as chief executive, is its founder. The company's lead product is Aversa, which it describes as 'abuse-deterrent transdermal technology', which incorporates aversive agents to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, specifically opioids. Its first application is its abuse-deterrent fentanyl transdermal patch, which it is developing to provide clinicians and patients with extended-release chronic pain relief. It is awaiting regulatory clearance for this product in the US. The company has operations in Florida, Georgia, and North Carolina, and recently began its expansion back to Dublin. READ MORE What lightbulb moment prompted you to start-up in business? It was originally a thesis idea. I had noticed a patch that my dad wears and began wondering what other types of medications could be delivered that way that had not been explored yet. The thesis became a business plan, and Nutriband was registered in 2012. Describe your business model and what makes your business unique. We structured the company in a unique way, using capital markets and a public listing approach. We listed on the OTC Markets in 2016 and started using stock to purchase companies and technologies in place of cash. This helped us to avoid raising expensive early capital and retain a major equity stake in the company today, even after an eventual qualification to list on the Nasdaq (in New York) in 2010. We also do not develop new drug applications. We take existing generic medications and use our technologies to improve upon those and relaunch them as a branded product again. What is your greatest business achievement to date? Growing the company to a level where we qualified to list on the Nasdaq Stock Exchange and getting to ring the opening bell. What was your back-to-the-wall moment and how did you overcome it? We almost got sued by the SEC (The US Securities and Exchange Commission) for an accidental erroneous disclosure in one of our filings while on the OTC markets. At first, we thought it could be explained. However, it grew to the point where they were doubling down. We hired an excellent attorney with SEC experience and eventually settled the issue in a cease-and-desist, no-admit, no-deny agreement. This led to our back-to-the-wall moment, where, while running on fumes financially, we received a rejection from Nasdaq in our first application. After a couple of days of self-pity, we got back to work, raised some working capital with existing shareholders, and grew the company's equity by $7.5 million (€6.4 million) over the course of the next year. We reapplied to list again successfully. What moment would you cite as a turning point for the company? Credibility provided by our Nasdaq listing and subsequent partnership with Kindeva Drug Delivery (formerly 3M Drug Delivery), where Kindeva supplied their generic approved fentanyl patch for us to add our technology to. What were the best and the worst pieces of advice you received when starting out? The worst advice was that banks and institutions have your company's best interests at heart. I firmly believe that today, Wall Street is built on companies failing, not succeeding. Describe your growth funding path. We were reluctant to raise expensive capital early on and instead listed the company to use stock as an acquisition currency to grow. Our gamble on this paid off, and although we raised modest cash along the way, we were able to build Nutriband without any significant seed or angel rounds. We reached a market capitalisation of $120 million (its market value currently is about $75 million), and we have been able to maintain stable and steady control as a result of the minimal capital rounds. We turn down anywhere from $5 million to $15 million on a weekly basis from funds and institutions because we do not need it. We are not in the business of raising money, and having as little dilution as possible is a core focus for us as a company. How will your market look in three years and where would you like your business to be? For our first product, we are expected to reach annual revenues of $200 million. Our second product is independently estimated to have upwards of $135 million in yearly revenue. We are targeting the billion dollar club before the end of 2027. What are your annual revenues and profits? We are not yet profitable, as is typical with clinical development-stage companies. However, we also contract manufacture sports tapes and products for brands such as Reebok and KT Tape. Our target revenue from this source for the financial year to the end of January 2026 is $3 million * . This goes towards operational costs and reduces our clinical burn. Why have you decided to seek a nomination for the presidency? It's never been a more important or relevant time in our history for a young president, particularly with the average age just under 40. I would be hoping that having a younger president would help narrow the division we're seeing in the country at the moment and that we can work together to tackle the issues, particularly the housing crisis. The younger generation aren't feeling very enthusiastic that their voices are being heard. What impact will this move have on your business? The company is in very safe hands and the biggest asset at the company is the team. We've got a very definite plan and timeline between now and Christmas on what needs to be achieved. Whether I'm in there or not that timeline needs to be adhered to. The company is motoring along fine. Stepping aside is not something that I think will fundamentally affect the opportunity for the company. What happens if you win? There are mechanisms where I can put the shares into a trust. I would be very proud that it was a company that I started and be very keen to still follow the journey, just not as CEO. Nutriband as a whole is going to do a lot of will help a lot of people who are dealing with addiction and people who are dealing with pain. *An earlier version of this article stated a higher target figure for contract manufacturing, which has since been revised by the company.
Extra.ie
8 hours ago
- Extra.ie
Two life-changing wins for Irish EuroMillions players as counties revealed
There were two huge wins in Ireland for the EuroMillions on Friday night, as the jackpot is set to reach its cap once again. The EuroMillions jackpot has once again reached its €250million jackpot cap, just two months after a Cork family syndicate won the same amount back in June. Despite no winners of the jackpot, two players in Limerick and Kildare have something to celebrate after they both won €500,000 in the EuroMillions Plus draw after they matched five numbers. There were two huge wins in Ireland for the EuroMillions on Friday night, as the jackpot is set to reach its cap once again. Pic: Derick P. Hudson/Shutterstock. The winning numbers on Friday (August 15)'s EuroMillions draw were 10, 34, 37, 38 and 43. 'Huge congratulations to our EuroMillions Plus winners in Co. Limerick and Co. Kildare, who have each won €500,000 – a fantastic start to their weekends!' National Lottery spokesperson Emma Monaghan said. 'While there was no winner of the EuroMillions jackpot worth €232,174,804, in total, over 70,000 players in Ireland won prizes in the EuroMillions and Plus games.' The EuroMillions jackpot has once again reached €250million — just two months after a Cork family syndicate won the colossal amount, buying their ticket from Clifford's Centra (pictured). Pic: Mac Innes Photography The National Lottery is urging all players in the Limerick area to check their tickets carefully, while an email notification has been sent to the online Kildare player. Contact the National Lottery prize claims team on 1800 666 222 or email claims@ to arrange the collection of your prize. Meanwhile, the EuroMillions jackpot has rolled over once again to its €250million jackpot — which was last won in Ireland back in June of this year — while the regular Lotto jackpot has reached an estimated €15.5million. Players dreaming of becoming Ireland's newest Lotto winner are reminded that tickets for tonight's draw can be purchased in-store, through the National Lottery app or at ahead of the 7.45pm cut off time on Saturday (August 16).
Irish Times
8 hours ago
- Irish Times
The Irish Times view on Budget 2026: put the focus on what is important
Over the next couple of weeks, as the Autumn political season starts to kick in, debate on October's budget will get underway in earnest. As ever, there will be a cacophony of demands from interest groups and lobbyists, looking for more spending or lower taxes for their particular cause. The job of the Government, of course, is to look through the noise to what is important. Despite the generous amount of €9.4 billion set aside for budget measures, this will not be easy. Money will be quickly eaten up through spending pressures in providing State services. Plans to hike vital investment expenditure need to be allowed for. And the demands on the table already would take up the €1.5 billion set aside for tax reductions a few times over. Yet while the choices will be sharp in some areas, context is needed. This is not shaping up to be a 'tough' budget. The promised package is still nearly three times the size of the last pre-Covid budget in 2019. The first job of the Government, indeed, is to start returning annual budgets to more sustainable levels, reducing them from the huge spending rises required during Covid-19 and to tackle the cost-of-living crisis. Claims that households are still squeezed need to be met in two ways. One is by appropriate increases in welfare and other support packages. The other is by continuing to improve the provision of services in areas such as health, education and childcare. These are much more effective in the longer-term than another round of universal cash supports. But by engaging in a blatant pre-election manoeuvre last year to repeat these 'once-off' supports again, Ministers have created a rod for their own back this time around. READ MORE Statements from Ministers that there would be no cost-of-living package this time appear to have become more equivocal in recent weeks. But giving a lot of money out again through these payments to all households is an inefficient use of State cash. If the Government does not bring this process to an end in the first budget of its new term, then – barring a big squeeze on the State finances – it never will. The plan to increase vital State investment is a key reason why there needs to be some restraint elsewhere. Realistic budgeting for the provision of State services also needs to be restored, ending the annual overruns in areas like health. Relying on corporate tax to keep outperforming as a way to pay for spending coming in ahead of target each year is not a good strategy. The other reason for caution is the uncertainty faced due to the policies of Donald Trump. Despite the trade deal between the EU and US, the economic and political backdrop for Ireland remains risky and unpredictable. Having cash in reserve and pursuing a strategic approach have seldom looked more important.
